SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.

Authors
Symonds, R P
Davidson, Susan E
Chan, S
Reed, N S
McMahon, T
Rai, D
Harden, S
Paul, J
Affiliation
University of Leicester, Department of Cancer Studies & Molecular Medicine, Leicester, UK.
Issue Date
2011-10

Metadata
Show full item record
Abstract
The aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.
Citation
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. 2011, 123 (1):105-9 Gynecol. Oncol.
Journal
Gynecologic Oncology
URI
http://hdl.handle.net/10541/229168
DOI
10.1016/j.ygyno.2011.06.001
PubMed ID
21723596
Type
Article
Language
en
ISSN
1095-6859
Collections